DA Davidson Weighs in on Clorox's FY2025 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX - Free Report) - DA Davidson issued their FY2025 earnings per share estimates for Clorox in a research note issued to investors on Wednesday, February 5th. DA Davidson analyst L. Weiser anticipates that the company will post earnings per share of $6.65 for the year. DA Davidson has a "Neutral" rating and a $169.00 price target on the stock. The consensus estimate for Clorox's current full-year earnings is $7.15 per share. DA Davidson also issued estimates for Clorox's FY2026 earnings at $6.32 EPS.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported $1.55 EPS for the quarter, topping analysts' consensus estimates of $1.39 by $0.16. Clorox had a net margin of 6.38% and a return on equity of 316.87%. During the same period in the previous year, the firm posted $2.16 earnings per share.

A number of other research firms also recently commented on CLX. Barclays lifted their target price on Clorox from $130.00 to $140.00 and gave the stock an "underweight" rating in a report on Wednesday, February 5th. TD Cowen upgraded shares of Clorox from a "sell" rating to a "hold" rating and increased their price objective for the stock from $155.00 to $170.00 in a research note on Wednesday, November 6th. Wells Fargo & Company boosted their target price on shares of Clorox from $157.00 to $161.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 4th. Royal Bank of Canada reiterated a "sector perform" rating and set a $150.00 price objective on shares of Clorox in a research note on Thursday, January 30th. Finally, Evercore ISI upped their target price on Clorox from $145.00 to $155.00 in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $158.21.

Clorox Stock Performance

CLX stock traded up $0.87 during midday trading on Friday, reaching $148.01. The stock had a trading volume of 472,473 shares, compared to its average volume of 1,334,355. The company has a debt-to-equity ratio of 20.52, a quick ratio of 0.62 and a current ratio of 0.94. The firm has a fifty day simple moving average of $160.68 and a two-hundred day simple moving average of $159.16. The stock has a market cap of $18.32 billion, a PE ratio of 40.39, a P/E/G ratio of 2.52 and a beta of 0.42. Clorox has a 52-week low of $127.60 and a 52-week high of $171.37.

Clorox Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 29th will be issued a $1.22 dividend. This represents a $4.88 annualized dividend and a dividend yield of 3.30%. The ex-dividend date of this dividend is Wednesday, January 29th. Clorox's dividend payout ratio (DPR) is presently 133.33%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CLX. Mizuho Securities USA LLC raised its holdings in shares of Clorox by 46,877.8% in the third quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company's stock worth $733,095,000 after acquiring an additional 4,490,421 shares during the last quarter. Ilex Capital Partners UK LLP lifted its holdings in Clorox by 512.7% in the 3rd quarter. Ilex Capital Partners UK LLP now owns 542,110 shares of the company's stock valued at $88,315,000 after purchasing an additional 453,624 shares in the last quarter. International Assets Investment Management LLC raised its position in shares of Clorox by 424.9% in the third quarter. International Assets Investment Management LLC now owns 538,576 shares of the company's stock valued at $877,390,000 after buying an additional 435,971 shares during the last quarter. Amundi raised its holdings in Clorox by 42.6% in the 4th quarter. Amundi now owns 1,032,283 shares of the company's stock valued at $165,816,000 after acquiring an additional 308,234 shares during the last quarter. Finally, Boston Trust Walden Corp increased its stake in Clorox by 5,442.5% in the third quarter. Boston Trust Walden Corp now owns 273,908 shares of the company's stock valued at $44,622,000 after purchasing an additional 268,966 shares during the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.